Abstract: Drug-drug interactions are increasingly common, as patients are getting older and the number of drugs per patient is increasing. In this study, we investigated to which extent potential drug-drug interactions originated from single or multiple prescribers. All patients attending any of 20 primary healthcare centres were included in a retrospective observational cohort study. Data on all prescriptions to these patients, irrespectively of the prescriber, were collected for two 4-month periods. Potential drug interactions were identified using the drug-drug interaction database SFINX. Interactions were classified with respect to the workplace of the prescriber, and the prevalence of interactions according to origin was analysed. We found that the drug interactions were significantly more common when the drugs were prescribed from different healthcare centres, compared with drugs prescribed from the patients' primary healthcare centre only. One explanation for this increased risk of drug interactions could be that the prescribers at different primary healthcare centres do not share the same information concerning the total medication list of the patient.
Drug-drug interactions (DDIs) are an increasing risk in health care, as patients are growing older and receive more drugs per patient [1, 2] . Elderly people are also at higher risk because of physiological changes; reduced renal function in particular. Drug-drug interactions may result in either a lack of clinical effect or cause adverse drug reactions. Irrespectively, they might increase morbidity and mortality. In a register study including the total population of Sweden (9.3 million), 35.5 million prescriptions were dispensed during a 4-month period, 7% of which resulted in potential DDIs. Half of these had the potential to lead to a decrease in drug effect, the other half to an increase in effect and adverse drug reactions [3] .
In order to make a correct analysis of potential drug interactions, the prescriber must have both a general knowledge about drug interactions and specific information about the complete medication list of the patient. Our group has developed a database for drug-drug interactions, which is now linked as a clinical decision support directly to most electronic health record systems in Sweden [4] . The database contains information regarding more than 19,000 potential drug-drug interactions, relating to approximately 1300 active substances. Even though physicians can be expected to recognize the most common and important risks related to DDIs, it is an unachievable task for the individual prescriber to keep all information updated and in mind. In a previous study in a set of 15 primary healthcare centres (PHCs), we were able to show a 17% reduction in severe potential DDIs among 73,000 pharmacy-dispensed prescriptions after the introduction of the drug-drug interaction decision support system into the electronic health record system [5] . Still, many patients are at risk of experiencing adverse drug-drug interactions, as shown in the study by Holm and coworkers [3] . Is the high prevalence of possible drug-drug interactions due to a lack of knowledge about the interactions or a lack of knowledge of the patient's complete medication list or both?
Primary healthcare centres in Stockholm accounted for an average of 27% of all doctor consultations, and 32% of all prescriptions to the population in the corresponding primary care districts [6] . There may be limited time to take a full medication history, and patients may assume that the doctor already possesses the relevant information, or may easily forget to relate information concerning, for example contraceptives or vitamins. Patients in Stockholm can visit any healthcare provider by their own choice. It is also possible to seek specialist care without a referral. A large discrepancy between the drug lists in the electronic health records of different caregivers, compared with the drugs actually dispensed to the patient, has been shown in Stockholm [7] . Unless the physician obtains a thorough medication history, and the patients are well aware of every drug they take, there is a risk of missing important information concerning drug-drug interactions.
In this study, we aimed to investigate the prevalence of potential DDIs in primary health care in the Stockholm urban locality. The primary objective was to determine to what extent potential DDIs were caused by prescriptions from the same practice or by concomitant prescribing from different healthcare providers. 
Materials and Methods
Inclusion of primary healthcare centres. The study was a retrospective observational study including data from patients visiting any of twenty primary healthcare centres (PHCs) in the Stockholm urban locality. This region inhabits about 1.3 million people [8] .
In total, twenty PHCs were recruited out of the 164 PHCs existing in the area. Inclusion of PHCs was performed through a stratified randomization procedure to avoid selection of PHCs in only a specific area of Stockholm. Hence, the PHCs included are assumed to be representative for the PHCs in Stockholm. PHCs were recruited through a telephone contact with the head of PHCs, and informed consent was collected. Only one contacted PHC declined to participate. Inclusion criteria were the existence of an electronic health record system including clinical decision support for DDI:s (SFINX). Nineteen PHCs with access to computerized drug records shared between different practices were excluded.
Definition of 'home primary healthcare centre'. Most patients in Stockholm are listed at a general practitioner (GP) in a PHC. A PHC shares the information for one patient between all physicians. Therefore, physicians within the same PHC have the possibility to see the same information concerning the patients' medications. Analysis was therefore made on a PHC level and not on individual prescriber level.
All drugs prescribed from prescribers with other workplace codes than the home PHCs were considered as 'other prescribers', who do not have the possibility to electronically retrieve the complete medication list of the patient. These 'external prescriptions', dispensed to the same patient during the study period, were treated as one group, without the possibility to identify individual PHCs or physicians.
The study objects were all patients from the included PHCs, who were dispensed one or more drugs during the study period. Prescription data were collected from the Swedish Prescribed Drug Register [6] . This register contains information about all prescribed drugs dispensed to the entire Swedish population. No drugs used in inpatient care, or drugs purchased by patients without prescriptions, that is OTC drugs, are included in the register, or in this study.
All prescriptions issued during the two study periods were analysed for all patients included. The prescriptions were coded as either prescribed by the home PHC or by any other prescriber. If a patient visited more than one of PHCs included in this study, the PHC from which the patient received the highest number of prescriptions (or if equal numbers, the most recent) was classified as the home PHC.
Two 4-month periods were chosen to adjust for seasonal differences in prescribing patterns for, for example antibiotics and antihistamines [9, 10] . All drugs dispensed to one patient within one of the 4-month periods are assumed to be used concomitantly. A 4-month period was chosen as patients in Sweden can purchase drugs for chronic use for time periods of 3 months. As package sizes (e.g. 100 tablets) allow the patient to take out their medication after more than 90 days, a 3-month period could lead to an underestimation of DDIs between chronic medications. This has been confirmed analysing the waiting time distribution, identifying first time users of all major pharmacological groups after a drug-free run-in period [11] .
Analysis of drug-drug interactions. The drug-drug interaction database SFINX contains clinically relevant interactions for all drugs available on the Swedish market [12] . All interactions in the database are classified regarding their clinical relevance (D to A) and level of documentation (4 to 0). The analysis was limited to DDIs classified as D (the combination is best avoided) and C-interactions (the interaction can be handled, e.g. by dose adjustment).
A software program created two drug lists for each patient: one included all drugs from the home PHC and another with all drugs from other caregivers, which made it possible to determine the origin for each potential DDI, as classified into three groups:
1 DDI due to two drugs prescribed from the home PHC (= 'home PHC group'). 2 DDI due to one drug prescribed from the home PHC and the other drug from another prescriber (= 'between group'). 3 DDI due to both drugs prescribed from other prescribers (= 'other group').
Drug-drug interactions were analysed using a software program which included all drugs dispensed to a patient during each of the study periods. Duplicate prescriptions (same substance and drug form) were eliminated. The two different drug lists for each patient were reduced for duplicates separately. This means that a patient could still have two drugs with the same active substance, where one was prescribed by the home PHC and one prescribed elsewhere.
Data analysis. The number of unique prescriptions per patient was calculated. All prescriptions with the same ATC code, same active substance and prescribed by the same prescriber (PHC or other) were classified as being a unique prescription. If a patient had issued more than one package of a generic drug from the same prescriber during the 4-month period, this was considered as one prescription. If a patient had issued one prescription of the same drug from the PHC and one from another prescriber, this was set as two prescriptions. Depending on the number of the two types of prescriptions, the number of possible interactions pair in a single patient (i.e. the total number of two-drug combinations that could be derived from all drugs used concomitantly during a 4-month period by an individual patient) was calculated for the three possible categories of drug interactions (within PHC, between PHC and other and between other prescriptions). Patients with only one prescription were excluded from the drug interaction analysis.
To adjust for the increasing risk of drug interactions with an increasing number of prescriptions, the prevalence of interactions compared to the number of possible interaction pairs within the three groups was analysed using v 2 -test with Bonferroni correction for multiple testing. All statistical analyses were performed using R 3.0.2 [13] .
The study was approved by the ethics committee in Stockholm (DNR: 2007/1627-31/4).
Results
Data analyses were based on data from 125,287 patients who had been dispensed drugs prescribed at any of the 20 PHCs within the included time periods. Patients had a median age of 51.2 years, and 59.7% were women. In total, 556,453 unique prescriptions were included in the analysis. Among these, 67% (n = 370,839) were issued from the home PHC and 33% (n = 185,614) from other prescribers. More than half (n = 65,895) of the patients had received one or more prescriptions from other prescribers.
Patients were exposed to 27,543 C and 3025 D classified drug interactions. The majority of the interactions were related to prescriptions issued outside of the patient's home PHC, either interactions between home PHC-prescribed drugs and drugs prescribed by other prescribers (for C 28% and D 35%), or between prescriptions from one or several other prescribers (C 52%, D 39%) ( fig. 1) . A summary of the ten most common drug-drug interactions within each category (within home PHC, between home PHC -other; between other-other) is presented in table 1. As expected, the risk of an interaction is increased by increased number of drugs a patient is using, as illustrated in fig. 2 .
Analysis of the fraction of interactions per possible interaction pair showed that the number of D-interactions per possible interactions pair was 63% higher in the 'between group' than in the 'home PHC group'. The number was 156% higher in the 'other group' than in the 'home PHC group'. C-interactions per possible interaction pairs were 67% more common in the 'between group' and 30 times higher in the 'other group' than in the 'home PHC group' (fig. 2 ). All these differences were highly statistically significant (p < 0.00001), also after Bonferroni correction.
Among the D-interactions, the combination of tetracyclines with chelate-forming agents and potassium prescribed with potassium-sparing agents was most common. Half of the D-interactions were pharmacokinetic and half pharmacodynamic. The most common C-interactions were between NSAID and antihypertensives and between NSAID and diuretics. Pharmacodynamic interactions were more common (70%) on the top-ten list for C-interactions than pharmacokinetic interactions (30%). In all cases, the potential drug-drug interactions were most often caused by prescriptions issued outside of the patient's home PHC (tables 2 and 3).
Discussion
According to our findings, potential drug-drug interactions in the primary healthcare settings arise more often as a result of prescriptions from multiple prescribers than from a single caregiver prescribing multiple drugs. Thus, one common patient's drug list and communication between different caregivers must be considered important tools, besides the knowledge about drug interactions, in preventing adverse outcome or lack of effect of drug treatment as a result of drug-drug interactions. Even though a majority of all drug prescriptions were issued by the patient's home PHC, the risk of a new prescription leading to a possible drug-drug interaction was significantly higher for those prescriptions that were issued outside of the home PHC. This was true for absolute numbers, as well as for the frequency of possible DDIs adjusted for the total number of drugs per patient. Thus, the increased risk of possible drug-drug interactions with multiple prescribers is not merely a result of patients seeking several caregivers having more prescriptions.
We found no other studies addressing the specific question of whether DDIs arise from prescriptions from the same or from different prescribers. Several researchers have pointed out the risk of less appropriate drug treatment as a result of multiple prescribers in general. Olsson et al. [14] demonstrated a negative correlation between quality of prescribing, as defined by several different quality indicators, including Cand D-interactions, and number of prescribers per patient among 3705 nursing home residents. In a cohort of 405 elderly outpatients, each additional prescriber increased the person's odds of reporting an adverse drug event by 29%, as shown by Green et al. [15] . In a publication titled 'Do too many cooks spoil the broth?', Tamblyn et al. report on the prevalence of potentially inappropriate drug combinations in nearly 5200 elderly outpatients. They found that approximately one-fifth of inappropriate drug combinations resulted from prescribing by multiple physicians. Furthermore, the number of prescribing physicians was the most important risk factor for inappropriate drug combinations, with an odds ratio of 1.44 to 1.71, depending on the group of drugs studied [16] .
In contrast, Vingerhoets et al. [17] found that the number of prescriptions was the most important predictor of inappropriate prescribing in 200 elderly patients, whereas the number of physicians visited by each patient was not independently associated with poor prescribing in a multivariate regression analysis.
Rinner et al. recently published a study estimating the effect of a future shared electronic health record system on the possibility to detect drug-drug interactions and duplicate Fig. 1 . The first pie illustrates the distributions of prescriptions from the primary healthcare centres and other prescribers. The second pie shows the distribution of the D-interactions home PHC + home PHC, home PHC + other (= 'between' group) and other + other (= 'other' group) and the third pie similarly shows the distribution of C-interactions. prescriptions in an Austrian population of more than one million people. They concluded that the number of warnings for interactions and duplicates would increase by 17%, should all the medications be visible in the same system, as compared with the current situation, where only prescriptions issued by a single healthcare provider can be checked [18] . In our study, the risk of potential drug-drug interactions was markedly higher in the group 'other prescribers'. We can only speculate that this increased risk is due to a lack of knowledge of the patient's complete medication list. There may also be other possible explanations. Other prescribers in this context may equal specialist caregivers in for example gynaecology, ophthalmology or psychiatry, with possibly less focus on the patients other illnesses and medications, and thus a less holistic approach than the 'house doctor' of the home PHC. Additionally, other prescribers may have been consulted for more acute, temporary conditions, in which situations there may also be less focus on drug-drug interactions. However, combinations like digoxin-verapamil or calcium channel blockers-enzyme inducing anticonvulsants, which to 90% were caused by prescriptions from other prescribers are not drugs for only temporary conditions. A much higher frequency of, for example the combination of warfarin with NSAIDs or metronidazole, or fluconazole with oral antidiabetics could result from such situations. Nevertheless, these drug combinations may confer serious risks to the patient and should be avoided.
Among D-interactions, about half were pharmacokinetic and half pharmacodynamic. In general, all D-interactions should be avoided although there are occasions when the combinations are beneficial (e.g. low-dose acetylsalicylic acid-warfarin, verapamil/diltiazem-beta-blockers). Pharmacodynamic Chelate formation includes substances binding to the other drug preventing absorptions (e.g. calcium, magnesium, aluminium). CYP2D6-inhibiting antidepressants (e.g. fluoxetine, paroxetine) reduce the effect of codeine and tramadol. interactions were most common among the top-10 C-interactions (70%). Most common was the risk of decreased efficacy of antihypertensive treatment due to concomitant NSAIDs. If the blood pressure is well monitored, this combination may be justified. One example of a potentially serious drug interaction is the one between doxycycline and proton pump inhibitors which may result in therapeutic failure.
A strength of the present study is that it includes a large group of patients and dispensed prescriptions during two different time periods. Also, data from the Swedish prescribed drug register are reliable to include all prescriptions for outpatients. We do not have information concerning drugs purchased over the counter or administered during hospital stays, but we do not believe that such prescriptions would lead to fewer drug-drug interactions. Furthermore, it is a strength that we identify potential drug-drug interactions from the same data source as is available to prescribing physicians in this study, the SFINX database.
Weaknesses of the study include the lack of specific knowledge concerning the 'other prescribers'. These may be either other general practitioners or other types of specialists with a narrower focus on the patients' situation. We do assume that all drugs prescribed within 4 months are taken concomitantly, which may lead to an overestimation of the risk of drug-drug interactions. Patients may also have been instructed to temporarily stop a drug treatment during for example a short course of antibiotic treatment or may separate the drug intake within the day to avoid some interactions, as those of chelating agents leading to reduced drug absorption.
We have observed, as many researchers before us, that the risk of potential drug-drug interactions increases with the number of drugs prescribed to each patient, but also that such interactions are much more likely to arise from two prescriptions by different prescribers. In short, it can be concluded that knowledge about drug-drug interactions, as supplied by a decision support system, is not enough to avoid unfavourable drug combination. We advise that an easily accessible common drug list included in the electronic healthcare record is a necessary tool to secure an optimal drug treatment in a patient.
